Akebia Therapeutics (AKBA) Misses Q1 EPS by 2c

Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $32.6 million versus the consensus estimate of $46.33 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• Akebia Therapeutics strengthens Vafseo patent portfolio with new grant